Purine biosynthesis enzyme

Purine biosynthesis enzymes form a highly coordinated metabolic pathway responsible for the de novo synthesis of purine nucleotides such as AMP and GMP, which are essential building blocks for DNA and RNA, as well as energy carriers (ATP, GTP) and signaling molecules (cAMP)[1][2][3][4][6]. This pathway is catalyzed in 10 steps by six major enzymes: amidophosphoribosyltransferase (PPAT), trifunctional GART, phosphoribosyl formylglycinamidine synthase (FGAMS), bifunctional PAICS, adenylosuccinate lyase (ADSL), and bifunctional ATIC[3][4][6]. In eukaryotes, these enzymes assemble into a subcellular multi-enzyme complex termed the purinosome, which localizes near mitochondria and microtubules and dynamically responds to cellular purine demand[1]. Dysregulation of this pathway is associated with cancer, immunodeficiencies, and metabolic diseases like gout. Many drugs (immunosuppressive, anti-proliferative, and anti-gout agents) act by inhibiting key purine biosynthesis enzymes, making them important therapeutic targets[2]. This entry is problematic as presented, because “DNA” and “RNA” themselves are not enzymes nor typical drug targets; the precise target should be “Purine biosynthesis enzymes” and, where possible, the individual enzyme should be specified (e.g., IMPDH, GART, PPAT). DNA and RNA, while built from purine biosynthesis pathway products, are not enzymes and should not be grouped with enzymatic therapeutic targets[2][5].

Other names

Purine pathway enzymeDe novo purine biosynthesis enzymePurinosome component

Inhibition of enzyme activity (e.g., blocking IMPDH or PRPP amidotransferase) Interference with nucleotide synthesis Inhibition of cell proliferation Modulation of cellular purine pools